A groundbreaking study by the National Institutes of Health (NIH) is shifting the conversation around hormone therapy and ...

Master injector Alexander Tirado, who brings unmatched passion and intimate knowledge of multiple disciplines, has been ...

A wave of menopause-related legislation has been introduced across the United States this year, leading to possible shifts in ...

While Astellas’ Veozah was the first neurokinin 3 (NK-3) receptor antagonist approved for menopause, Lynkuet is the first ...

During a live event, Jahan Aghalar, MD, discussed key NCCN-recommended oral therapies and landmark trials for metastatic ...

Pfizer and Astellas’ Xtandi (enzalutamide) has improved overall survival (OS) in patients with non-metastatic ...

Skin health experts debunk collagen myths, like whether or not collagen supplements really work, and all the ways you can ...

The participants in the trial – similar to two-thirds of breast cancer patients overall - had tumors that use the hormones estrogen and progesterone to grow. The goal of so-called endocrine therapy is ...

Young patients with advanced Hodgkin's lymphoma, a cancer of the lymphatic system, now have a better chance of having their ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has cleared the oral neurokinin (NK) 1 and 3 antagonist, under the Lynkuet brand name, for the treatment of moderate to severe vasomotor ...

"Everyone I spoke to seemed to say it was an impossible challenge to take on, and weight gain was inevitable", said Bev ...